Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.

Peasland, A; Wang, L-Z; Rowling, E; Kyle, S; Chen, T; Hopkins, A; Cliby, W A; Sarkaria, J; Beale, G; Edmondson, R J; Curtin, N J

Peasland, A; Wang, L-Z; Rowling, E; Kyle, S; Chen, T; Hopkins, A; Cliby, W A; Sarkaria, J; Beale, G; Edmondson, R J; Curtin, N J.

Affiliation

Peasland A; Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne NE2 4HH, UK.

Br J Cancer ; 105(3): 372-81, 2011 Jul 26.

Article in En | MEDLINE | ID: mdl-21730979

Subject(s)

Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Cell Cycle Proteins/antagonists & inhibitors; Nitroso Compounds/therapeutic use; Ovarian Neoplasms/drug therapy; Protein Serine-Threonine Kinases/antagonists & inhibitors; Pyrimidines/therapeutic use; Animals; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms/genetics; Cell Cycle/drug effects; Cell Line, Tumor; DNA Damage/drug effects; DNA Mismatch Repair/drug effects; Drug Evaluation, Preclinical; Female; Genes, p53; Humans; Leukemia L1210; Mice; Ovarian Neoplasms/genetics; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Pyrimidines / Breast Neoplasms / Protein Serine-Threonine Kinases / Cell Cycle Proteins / Antineoplastic Agents / Nitroso Compounds Type of study: Diagnostic_studies Limits: Animals / Female / Humans Language: En Journal: Br J Cancer Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google